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Abstract
In the airways of those with cystic fibrosis (CF), the leading pathophysiological hypothesis is that an ion channel defect
results in a relative decrease in airway surface liquid (ASL) volume, producing thick and sticky mucus that facilitates the
establishment and progression of early fatal lung disease. This hypothesis predicts that any successful CF airway treatment
for this fundamental channel defect should increase the ASL volume, but up until now there has been no method of
measuring this volume that would be compatible with in vivo monitoring. In order to accurately monitor the volume of the
ASL, we have developed a new x-ray phase contrast imaging method that utilizes a highly attenuating reference grid. In this
study we used this imaging method to examine the effect of a current clinical CF treatment, aerosolized hypertonic saline,
on ASL depth in ex vivo normal mouse tracheas, as the first step towards non-invasive in vivo ASL imaging. The ex vivo
tracheas were treated with hypertonic saline, isotonic saline or no treatment using a nebuliser integrated within a small
animal ventilator circuit. Those tracheas exposed to hypertonic saline showed a transient increase in the ASL depth, which
continued for nine minutes post-treatment, before returning to baseline by twelve minutes. These findings are consistent
with existing measurements on epithelial cell cultures, and therefore suggest promise for the future development of in vivo
testing of treatments. Our grid-based imaging technique measures the ASL depth with micron resolution, and can directly
observe the effect of treatments expected to increase ASL depth, prior to any changes in overall lung health. The ability to
non-invasively observe micron changes in the airway surface, particularly if achieved in an in vivo setting, may have
potential in pre-clinical research designed to bring new treatments for CF and other airway diseases to clinical trials.
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Introduction
To maintain normal lung function, it is essential that the
airways clear cellular debris or pathogens that deposit during
respiration. The surface of the conducting airways are covered
with microscopic hairs called cilia, located within the airway
surface liquid (ASL), that provide the driving force for mucociliary
clearance (MCC). The ASL comprises two layers, the periciliary
liquid (PCL) (typically 4–6 mm deep in the nasal airways of normal
mice), and an overlying mucus layer [1]. Debris, bacteria and
viruses are normally captured by the mucus layer and transported
along the airway surface away from the lungs via cilia action until
the material is directed into the oesophagus and swallowed. In the
case of larger airway debris or mucus materials, MCC can be
supplemented by cough mechanisms [2].
In cystic fibrosis (CF) a defect in the cystic fibrosis transmem-
brane conductance regulator (CFTR) gene produces a chloride-
ion channel defect in epithelial cells [1]. In the conducting airways,
this defect results in a reduction in the ASL volume [3,4] and
produces a relative dehydration of the airway surface such that
MCC is compromised. The thickened and sticky mucus cannot be
sufficiently cleared by MCC, resulting in retention of both mucus
and inhaled pathogens. These pathogens contribute to the
persistent infection that underlies the progressive lung disease
and decreased respiratory function that is typical of CF [2].
Although CF impairs the function of a range of other organ
systems, it is the chronic infectious airway and lung diseases that is
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e55822
"
"
"  Joint Senior Authors  
the primary cause of a decreasing quality of life and an early death
in most CF patients.
Therapies that focus on the correction of abnormal epithelial
cell ion transport or the CFTR defect itself are attractive as they
have the potential to alter lung disease progression and hence
patient prognosis [5]. Currently, the inhalation of hypertonic
saline or mannitol is used in the CF clinic to rehydrate the ASL by
altering the osmotic gradient across the airway surface, and
drawing water onto the airway cell surface [6,7,8]. Airway gene
therapies are designed to insert a correctly functioning copy of the
CFTR gene into the epithelial cells to correct the source of the ion
channel defect and, consequently, so restore ASL volume [9]. The
newest treatment for CF airway disease is the FDA approved drug
Ivacaftor, a chloride channel potentiator specifically for the
G551D CF mutation [10]. Regardless of their mechanism of
action, treatments that increase the airway surface liquid volume
and improve MCC, should improve quality of life and extend the
lifespan in people with CF [1].
Despite the opportunity afforded by these ASL modifying
treatments to alter disease progression, there are no rapid or direct
methods that non-invasively assess treatment effectiveness at the
primary site of action – the airway surface – where ASL volumes
are altered. In humans, CF health is currently estimated by
measuring changes in forced expiratory volume (FEV), and more
recently by studying changes in lung structural disease, as assessed
by CT [11]. These methods can indicate whether a treatment has
altered progression of established lung disease, but measurements
must be taken over several months. Similarly, disease must be
largely established to be detectable using these methods and hence,
they cannot detect the initiation of CF lung disease. Although ASL
volume measures have previously been estimated in airway
epithelial cultures [3,12,8] and in fragments of trachea [13], by
measuring the ASL height these methods are clearly not
compatible with in vivo monitoring. There exists a continuing
demand for a method that can immediately detect the presence of
CF airway surface disease, and provide immediate feedback in
treatment assessment. Direct measurement of the ASL volume (or
depth) before and immediately after treatment would enable early,
rapid and iterative treatment with the potential for modifying the
disease-establishment process.
We have developed a synchrotron x-ray imaging technique with
sufficient resolution and sensitivity to quantify the ASL depth
within an intact trachea [14,15]. The method uses short x-ray
exposures to capture images of the living airway, therefore
avoiding motion blur, and is amenable to in vivo application since
penetrating x-rays can image structures deep within the body at
very high resolutions. The ability to resolve soft tissue structures
using x-rays is realized by a mechanism called phase contrast.
Phase contrast x-ray imaging (PCXI) visualises changes in the
phase of the x-ray wavefield as well as changes in intensity. Phase
variations can be converted into an observable intensity image via
a variety of experimental set-ups that include propagation-based
imaging [16,17], analyzer-based imaging [18] and Talbot
interferometry with gratings [19,20]. It is difficult to capture
moving live biological activity with these latter two methods of
PCXI since they usually require either multiple exposures while
moving the optics, or a longer exposure to compensate for loss of
intensity in the optics.
Live animal imaging studies typically use propagation-based
PCXI, where a distance is introduced between the sample and
camera (typically tens of centimeters to a few metres), so that
bright-dark intensity fringes are propagated from sharp interfaces
between differing materials in the sample onto the detector/
camera, creating an image with enhanced edge visibility
[16,17,21,22]. Edges running in any direction are captured within
a single short exposure. However, propagation-based PCXI has
relatively limited contrast sensitivity (compared to other phase
contrast imaging methods) and cannot easily detect smoother
edges or subtle changes in thickness. In particular, we have
previously reported that propagation-based PCXI can readily
resolve the ASL-to-air interface, but the ASL-to-tissue interface
has hitherto not been directly visible since these two materials have
very similar densities and composition [14].
To obtain sufficient contrast resolution to image the ASL-to-
tissue interface, we have developed a Shack-Hartmann-like
[23,24,25] PCXI method. This method is sensitive to the
transverse gradients (mathematically, the first derivatives) present
in the sample, rather than the second derivative, as is the case with
propagation-based PCXI [26]. This additional sensitivity is
achieved by utilizing a single absorption grid, placed before the
sample (the airway), which also allows us to measure phase
variations in both directions within a single short exposure [14,27].
Our method can be illustrated in a visible light example by
analogy to the distorted shadow of a fence observed on the bottom
of a swimming pool. The sun (analogous to the ‘‘x-ray source’’)
illuminates the fence (the absorption ‘‘grid’’), and the fence-
patterned light passes through the water (here representing the
sample), landing on the bottom of the pool (the ‘‘camera’’). The
lens-like effect of the water surface will distort the shadow of the
fence when seen on the bottom of the pool. By looking at how the
fence pattern has been distorted by the water, an image describing
the water surface can be reconstructed. The airway sample has a
similar effect on the x-rays as the water does on the visible light -
changing the ray path of the light, without significantly decreasing
the intensity. In the same way the image of the pool surface can be
reconstructed, so can the image of the airway. Note that while
there will be low-contrast patterns on the bottom of the pool from
the water surface alone (analogous to propagation-based PCXI),
the addition of the high-contrast reference fence pattern will allow
more subtle surface variations to be detected, resulting in a more
sensitive imaging system.
This study utilised our grid-based imaging technique to examine
the ASL in an intact, fastly excised mouse trachea, maintained in a
warm biological saline bath. The ex vivo sample avoids the
confounding structures introduced by overlying tissue and skin
present, and so ex vivo imaging is the first step in measuring the
depth of the low-contrast ASL. Using this new imaging approach
we demonstrate here that ASL depth changes induced by
treatments can be rapidly and directly measured. The ability to
track ASL depth changes in ex vivo samples provides the basis for
non-invasive in vivo and long-term repeated imaging.
Methods
Ethics Statement
All animal experiments were approved by the Animal Ethics
Committee of SPring-8 (proposal 2011A1306) and the Women’s
and Children’s Health Network, Adelaide (AE805-12-2012). All
animals were humanely killed before surgery began to minimize
suffering.
Sample preparation
Immediately after humane killing by Nembutal overdose,
tracheas were removed as a single piece from the carina to the
cricoid cartilage from female C57BL/6 mice (total n = 15, ,19
grams body weight), using standard dissection techniques. Each
end of the trachea was sutured onto air-filled glass capillary tubes
(0.8 mm outer diameter), as shown in Fig. 1, and extended to
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mimic the in-animal between-cartilage lengths. After excision,
ciliary beat was visible via stereo-microscope through the wall of
the trachea, confirming active MCC. The capillaries were
connected to a flexiVent ventilator (SCIREQ, Canada), and the
arrangement submerged in 37uC phosphate buffered saline (PBS)
within a sealed tissue chamber (Living Systems CH-1, USA),
modified with the addition of a reduced depth x-ray imaging
section (to minimise x-ray absorption for high x-ray flux and short
exposures). The tissue-bath was mounted for imaging so that the
trachea was positioned vertically (Fig. 1) and the ventral side of the
airway was imaged. The ventral side was chosen to avoid multiple
edges appearing in the images, as can be present on the dorsal side
of the trachea where airway surface projection into the lumen can
occur due to the size of the underlying trachealis muscle (see Fig. 1).
To mimic in-animal conditions used in our live animal studies, the
trachea was ventilated with room air at 80 breaths/minute, a tidal
volume of 0.4 ml and a PEEP (positive end expiratory pressure) of
,3 cm H2O.
Each trachea was randomly assigned to receive either no
treatment, isotonic saline (0.7%) or hypertonic saline (7%) (with
n = 5 for each group).
Treatments were delivered using an Aeroneb Pro nebuliser
(Aerogen, Ireland), designed to produce 4–6 mm volume median
diameter (VMD) aerosols, with delivery controlled by the flexiVent
ventilator. Aerosols were delivered with 50% duty cycle, during
inspiration only, for a period of 90 seconds. Images were captured
immediately before treatment delivery, then at 3 minute intervals
after the initial imaging up to a total of 18 minutes (totaling seven
time-points). Ten images were taken at each time-point. A
mechanical shutter shielded the trachea from the x-ray beam
between image captures to minimise the radiation dose.
Imaging method
Imaging was performed at the SPring-8 synchrotron in Japan,
using the BL20XU beamline in the Biomedical Imaging Centre
(245 m from the storage ring). This undulator x-ray beamline
provides highly coherent x-rays for detailed phase contrast, high
flux for short exposures, and a suitably large area of illumination.
The x-ray energy was set at 25 keV, sufficiently high that sample
absorption did not lead to unacceptably long exposures and
sufficiently low that good phase contrast was achieved.
Images were captured using a pco.4000 (PCO imaging) CCD
camera, coupled to a 10 mm thick scintillator (to convert x-rays to
visible light) and a 506 microscope objective lens to give an
effective pixel size of 0.1860.18 mm. The CCD provided
400862672 pixels, hence a 7216497 mm field of view was
available. The 150 ms exposure time was sufficiently short that
ventilation induced movement of the airway surface did not create
movement blur in the images.
The simple experimental set-up is shown in Fig. 2, where an x-
ray source illuminated a gold absorption grid (25.4 mm period,
G1000HS-G3, Gilder Grids, UK), after which the grid-patterned
x-rays passed through the mouse trachea and propagated 1 metre
to the camera. Phase variations introduced by the mouse trachea
distort the intensity grid image that was captured by the camera.
The grid was imaged (‘‘Image without trachea’’ in Fig. 2) before
the trachea was introduced and this undistorted reference image
was then compared to each image of the grid and trachea (‘‘Image
with trachea’’ in Fig. 2) captured over the time-points before and
after treatment. The distortion the sample imparted on each part
of the grid image was determined using a cross-correlation
technique [14], which revealed how far and in which direction the
pattern was shifted at each pixel in the image. An image where the
intensity of each pixel is the shift in the horizontal direction at that
pixel position will describe the x direction gradient of the sample’s
thickness and density, as seen in Fig. 3a. In the case of a vertical
trachea, as seen here, the vertical component of the shift (the y
direction sample gradient) is very small and provides little
information, as the sample varies mainly in the x direction. The
two gradient images can be integrated together to give an image of
the total density-thickness [14], which is comparable to a
conventional clinical x-ray image (i.e. the intensity is directly
related to the thickness and density of the sample), Fig. 3b.
Since the sharp diagonal grid lines will intersect with the vertical
airway interfaces in the ‘‘Image with trachea’’, the spatial
resolution in the local position of the airway interface at the edge
of each grid line will be roughly equivalent to the resolution of the
imaging system (,1 mm). While the same local edge position
resolution will not be achieved in the space between grid edges,
our previous propagation-based PCXI data has indicated that at
these length scales (i.e. the vertical distance between grid edges – a
maximum of ,10 mm in this case) the interfaces will vary
smoothly (particularly the liquid interface, which has surface
tension), leading to an accurate measure down the length of
trachea in the field of view. This is in fact like taking an
interpolated average of measurements every ,10 mm down the
trachea length.
Analysis
ASL depth was measured by manually tracing both the airway/
ASL interface and the ASL/tissue interface in the sample gradient
image (Fig. 3a), tracking along between the dark/light bands of
each interface. The manual placement of these lines had an
acceptably high intraclass correlation of 0.992 (95% confidence
limits of 0.987–0.997) for independent placement by 5 different
scorers on 9 images. The mean distance was then computationally
measured between these two interface traces (airway/ASL and
ASL/tissue) for every row of pixels down the length of airway
present between cartilage rings. This measurement was repeated
Figure 1. Ex vivo trachea mounted vertically between air-filled
capillaries and submerged in a warm phosphate buffered
saline bath for imaging. The sample is arranged so that the imaged
ASL region is the ventral tracheal surface.
doi:10.1371/journal.pone.0055822.g001
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at each of the 7 timepoints, for each of the 15 mouse tracheas
(n = 5 for three ‘‘treatments’’), blinded to treatment.
Statistical analyses were performed using GraphPad Prism 5.
The ASL data was square root transformed to ensure normality
assumptions were met. Statistical significance was set at p = 0.05
and power = 0.8 and measures were analysed by two way repeated
measures ANOVA with Bonferroni multiple comparisons. The
depth measures are presented as scatter plots with means.
Results
A typical airway surface image obtained using the single-grid
PCXI method is shown in Fig. 3a, b and c. The interface between
the air-filled trachea and the ASL is clearly visible, with a steep
phase gradient (i.e. seen as increasingly dark/black) ending at the
ASL on the edge of the airway lumen. A less distinct line is seen
further to the right; this is taken as the ASL/tissue interface. This
latter interface is not visible using a standard propagation-based
PCXI set-up. The presence of both the ASL interfaces in our
images means that ASL depth measurements can be made. Note
the speckled regions at the top and bottom of the image are from
the tracheal cartilage rings. It can be seen that the ASL depth
increases after hypertonic saline is delivered (immediately after
Fig. 3a, 0 min) with the two interfaces moving further apart in
Fig. 3b and c.
From Fig. 3c, the total density-thickness image was calculated,
as shown in Fig. 3d. Although Fig. 3d is analogous to a
conventional x-ray absorption image, where near black tones
indicate the outside of the airway (since tissue and ASL have very
similar densities and hence very similar absorption) and white
tones indicate the airway lumen, the image of the thickness
gradient (3c) is considerably more amenable to precise measure-
ment of the ASL.
Figure 4 shows that there was a statistically significant increase
in ASL depth at 3, 6 and 9 minutes following hypertonic saline
delivery, compared to the no-treatment group. In terms of
absolute ASL depth, from a pre-treatment mean ASL depth of
10.6 mm for all groups, the hypertonic saline group reached an
average maximum of 20.3 mm.
There were no significant differences in ASL depth observed
between the normal saline and no-treatment groups.
The images in Fig. 3 also reveal the outer tissue interface, where
the PBS bath surrounds the excised airway. To evaluate the effect
of treatments on this surrounding tissue, measurements were also
taken of the outer tracheal tissue thickness, averaging the distance
between the ASL-tissue boundary and the tissue-bath boundary
over the length of the airway between cartilage rings, in the same
manner as the ASL depth measurements.
Figure 5 shows a statistically significant decrease in tissue
thickness was present immediately after hypertonic saline treat-
ment, with a trend showing a steady reduction in tissue thickness
to the final 18 minute assessment point. There were no significant
differences between the normal saline and no-treatment groups.
Figure 2. Single-exposure single-grid phase contrast x-ray imaging set-up, for imaging of a live trachea in a specially-built tissue
bath.
doi:10.1371/journal.pone.0055822.g002
Figure 3. Single-grid based image of the airway surface under
hypertonic saline treatment, showing the sample thickness gradient
in the x direction (the thickness gradient in the y direction is not shown
as most features run vertically and do not provide y-contrast) a) before
hypertonic saline treatment, b) 3 minutes after treatment, c) 6 minutes
after treatment and d) the projected thickness calculated from image c).
doi:10.1371/journal.pone.0055822.g003
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Discussion
This study has demonstrated that our single-grid phase contrast
x-ray imaging method [14] can visualise and quantify changes in
ASL depth in freshly excised mouse tracheas. The effects of
nebulised delivery of saline solutions of different tonicities on ASL
depth were successfully measured.
Treatment with hypertonic saline produced a statistically
significant increase in ASL depth, with the effect peaking 6–
9 minutes after treatment before returning to baseline by
12 minutes. Previous studies with normal human epithelial cell
cultures have found similar results [28,8], with the transient
increases in ASL depth also concluded by approximately 12 mins.
In those epithelial cell culture studies, the initial ASL depth was
approximately 10 mm (depending on mucus thickness) and
increased to approximately 30 mm. When isotonic saline was
delivered a slight but non-significant increase in total ASL depth
was observed. This is consistent with deposition of the nebulised
isotonic saline volume on the airway surface. We, therefore,
attribute the increase in ASL depth in the presence of hypertonic
saline to the osmotic imbalance driving water from and around
epithelial cells onto the airway surface.
The evidence for this is two-fold. First, since those tracheas
given hypertonic saline received the same volume of fluid as
tracheas in the isotonic group, it is unlikely that the ASL increase
came from simple deposition of a nebulised volume onto the
airway surface alone. Second, changes in the volume of tissue/
epithelial cells were observed, consistent with contribution of
cellular fluid to the ASL. This was particularly noticeable
immediately after treatment, as seen in Figure 5. This decrease
in ‘‘tissue thickness’’ immediately following hypertonic saline
delivery suggests that a volume of liquid left the epithelial cells
across the more water permeable apical membrane in response to
the aerosol-induced hypertonicity of the ASL. The decrease in
tissue volume was approximately equal to the increase in ASL
volume (around 10 mm), as would be expected. It is interesting to
note that the minimum tissue volume is observed immediately
following treatment, whereas the maximum ASL depth was on
average not observed until two timepoints later. It should,
however, be noted that we are observing only one view (or
projection) covering around 15% of the total height of the trachea,
hence liquid that is donated to the ASL by airway surface cells
may move in a non-uniform way around the airway surface in this
intervening time.
Figure 4. ASL depth as a function of time, in response to hypertonic saline (7%), isotonic saline (0.7%) or no treatment (No
Rx – Control). A statistically significant increase in the ASL depth occurred with hypertonic saline treatment at 3 minutes (** p,0.01), 6 minutes
(**** p,0.0001) and 9 minutes (*** p,0.001) compared to control.
doi:10.1371/journal.pone.0055822.g004
Figure 5. Change in tissue thickness (relative to initial thickness), as a function of time. A statistically significant difference (* p,0.05) in
thickness was present for the hypertonic saline group at 3 minutes compared to control.
doi:10.1371/journal.pone.0055822.g005
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These results confirm that our grid imaging method can directly
observe changes in ASL depth in ex vivo tissue samples. To our
knowledge, this is the first time that such direct measurements of
the ASL depth have been achieved in intact lengths of trachea. An
important feature of the imaging set-up is that it is compatible with
in vivo experiments without further modification. The primary
remaining challenges for future in vivo investigations relate to the
overlying anatomy which will tend to obscure the subtle tissue-
surface liquid interface in imaging intact animals, and the expected
x-ray dose, particularly for longitudinal or repeat imaging
necessary for treatment efficacy studies. In the first case, we have
some confidence from ongoing studies that simple steps such as
removing the fur and gently stretching and tethering the skin of
mice significantly ameliorates the effects of overlying structures
[22]. Continued detector improvements are contributing to dose
reductions via shorter exposure times. Other ongoing work at the
SPring-8 synchrotron has shown that repeat imaging studies are
possible, indicating that using these imaging methods to track
treatments over longer periods is technically feasible. Further
studies examining the effects of hypertonic saline, as well as other
pharmaceuticals that modify airway surface function, can now be
undertaken. Similarly, studies could examine differences after
treatments in wildtype mice, and in the b-ENaC and CF-knockout
mouse models.
Conclusion
The development of new treatments for the life-shortening lung
disease of cystic fibrosis is grounded in precise methods of airway
health monitoring. We have shown that a new method of phase
contrast x-ray imaging can directly measure the depth of airway
surface liquid in a living ex vivo airway, with micron resolution. In
the ex vivo airway, the increase in ASL depth in response to
hypertonic saline was of the magnitude and duration expected
from previous airway culture studies. This new imaging method
can assist in progressing in vivo animal model imaging of the
airways for the assessment of promising new treatments for cystic
fibrosis.
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